Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present ...

This story contains spoilers from “Are You Happy Now, That I’m on My Knees?,” the series finale of “Tell Me Lies,” now ...

Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET –– Webcast may be accessed here – MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ...

Registered attendees can request one-on-one meetings with Gain management via their Oppenheimer banking representative. If you are unable to attend the conference and would like to schedule a meeting ...

Format: Company Presentation and 1x1 Investor Meetings Date/Time: Thursday, February 26, 2026, at 10:00 am ET The presentation will be webcast live and archived in the Investor Relations section of ...

Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced its participation in the ...

CEO Mitchell Steiner stated that Veru is advancing its late-stage clinical pipeline, focusing on two oral small molecule drugs: enobosarm, a selective androgen receptor modulator for combination with ...

Oppenheimer Healthcare Life Sciences Conference: Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will ...

Q4 2025 earnings call: nsPFA clinical/regulatory timeline, Vybrance rollout, revenue trends, cash burn & outlook—read now.

U.S. District Judge Mark Kearney has denied a request by former VIPD Commissioner Ray Martinez to delay pre-sentencing detention by several months. He must now self-surrender to U.S. Marshals by ...

Adlai Nortye shifts strategy after Buparlisib trial failure, focusing resources on its pan-RAS inhibitor AN9025 and a newly ...

Kyntra Bio, with cash into 2028, refocuses on oncology. Key catalysts include a Feb 26 investor presentation and Phase 2 data for lead asset FG-3246 expected in H2 2026.